Compounds useful for treating allergic or inflammatory diseases

A compound of Formula (I):

• ##STR16## wherein:
• R.sub.1 is --CH.sub.2 -cyclopropyl, CH.sub.2 -C.sub.5-6 cycloalkyl, C.sub.4-6 cycloalkyl, C.sub.7-11 polycycloalkyl, (3- or 4-cyclopentenyl), phenyl, tetrahydrofuran-3-yl, benzyl or C.sub.1-2 alkyl substituted by 2 or more fluorines, --(CH.sub.2).sub.1-3 C(O)O(CH.sub.2).sub.0-2 CH.sub.3, --(CH.sub.2).sub.1-3 O(CH.sub.2).sub.0-2 CH.sub.3, and --(CH.sub.2).sub.2-4 OH;
• m is 0 to 2;
• n is 1 to 4;
• r is 1 to 6;
• X is YR.sub.2, halogen, nitro, NR.sub.4 R.sub.5, or formyl amine;
• Y is O or S(O).sub.m' ;
• m' is 0, 1, or 2;
• X.sub.2 is O or NR.sub.8 ;
• X.sub.3 is hydrogen or X;
• R.sub.2 is independently selected from --CH.sub.3 or --CH.sub.2 CH.sub.3 unsubstituted or substituted by 1 or more halogens;
• s is 0 to 4;
• R.sub.3 is hydrogen, halogen, C.sub.1-4 alkyl, CH.sub.2 NHC(O)C(O)NH.sub.2, halo-substituted C.sub.1-4 alkyl, --CH.dbd.CR.sub.8' R.sub.8', cyclopropyl optionally substituted by R.sub.8', CN, OR.sub.8, CH.sub.2 OR.sub.8, NR.sub.8 R.sub.10, CH.sub.2 NR.sub.8 R.sub.10, C(Z')H, C(O)OR.sub.8, C(O)NR.sub.8 R.sub.10, or C.tbd.CR.sub.8' ;
• Z' is O, NR.sub.9, NOR.sub.8, NNR.sub.8 R.sub.8, NCN, C(--CN).sub.2, CR.sub.8 CN, CR.sub.8 NO.sub.2, CR.sub.8 C(O)OR.sub.9, CR.sub.8 C(O)NR.sub.8 R.sub.8, C(--CN)NO.sub.2, C(--CN)C(O)OR.sub.9, or C(--CN)C(O)NR.sub.8 R.sub.8 ;
• Z" is C(Y')R.sub.14, C(O)OR.sub.14, C(Y')NR.sub.10 R.sub.14, C(NR.sub.10)NR.sub.10 R.sub.14, CN, C(NOR.sub.8)R.sub.14, C(O)NR.sub.8 NR.sub.8 C(O)R.sub.8, C(O)NR.sub.8 NR.sub.10 R.sub.4, C(NOR.sub.14)R.sub.8, C(NR.sub.8)NR.sub.10 R.sub.14, C(NR.sub.14)NR.sub.8 R.sub.8 C(NCN)NR.sub.10 R.sub.14, C(NCN)SR.sub.9, (2-, 4- or 5-imidazolyl), (3-, 4- or 5-pyrazolyl), (4 - or 5-triazolyl[1,2,3]), (3-or 5-triazolyl[1,2,4]), (5-tetrazolyl), (2-, 4- or 5-oxazolyl), (3-,4- or 5-) isoxazolyl, (3- or 5-oxadiazolyl[1,2,4]), (2-oxadiazolyl[1,3,4]), (2-thiadiazolyl[1,3,4]), (2-, 4-, or 5-thiazolyl), (2-, 4-, or 5-oxazolidinyl), (2-, 4-, or 5-thiazolidinyl), or (2-, 4-, or 5-imidazolidinyl);
• wherein all of the heterocylic ring systems may be optionally substituted one or more times by R.sub.14 ;
• Y' is O or S;
• R.sub.7 is --(CR.sub.4 R.sub.5).sub.q R.sub.12 or C.sub.1-6 alkyl wherein the R.sub.12 or C.sub.1-6 alkyl group is optionally substituted one or more times by C.sub.1-2 alkyl optionally substituted by one to three fluorines, --F, --Br, --Cl, --NO.sub.2, --Si(R.sub.4).sub.3, --NR.sub.10 R.sub.11, --C(O)R.sub.8, --CO.sub.2 R.sub.8, --OR.sub.8, --CN, --C(O)NR.sub.10 R.sub.11, --OC(O)NR.sub.10 R.sub.11, --OC(O)R.sub.8, --NR.sub.10 C(O)NR.sub.10 R.sub.11, --NR.sub.10 C(O)R.sub.11, --NR.sub.10 C(O)OR.sub.9, --NR.sub.10 C(O)R.sub.13, --C(NR.sub.10)NR.sub.10 R.sub.11, --C(NCN)NR.sub.10 R.sub.11, --C(NCN)SR.sub.9, --NR.sub.10 C(NCN)SR.sub.9, --NR.sub.10 C(NCN)NR.sub.10 R.sub.11, --NR.sub.10 S(O).sub.2 R.sub.9, --S(O).sub.m' R.sub.9, --NR.sub.10 C(O)C(O)NR.sub.10 R.sub.11, --NR.sub.10 C(O)C(O)R.sub.10, thiazolyl, imidazolyl, oxazolyl, pyrazolyl, triazolyl, or tetrazolyl;
• q is 0, 1, or 2;
• R.sub.12 is C.sub.3-7 cycloalkyl, (2-, 3- or 4-pyridyl), pyrimidyl, pyrazolyl, (1- or 2-imidazolyl), thiazolyl, triazolyl, pyrrolyl, piperazinyl, piperidinyl, morpholinyl, furanyl, (2-or 3-thienyl), (4- or 5-thiazolyl), quinolinyl, naphthyl, or phenyl;
• R.sub.8 is independently selected from hydrogen or R.sub.9 ;
• R.sub.8', is R.sub.8 or fluorine;
• R.sub.9 is C.sub.1-4 alkyl optionally substituted by one to three fluorines;
• R.sub.10 is OR.sub.8 or R.sub.11 ;
• R.sub.11 is hydrogen, or C.sub.1-4 alkyl optionally substituted by one to three fluorines;
• or when R.sub.10 and R.sub.11 are as NR.sub.10 R.sub.11 they may together with the nitrogen form a 5 to 7 membered ring optionally containing at least one additional heteroatom selected from O, N, or S;
• R.sub.13 is oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, or thiadiazolyl, and each of these heterocyclic rings is connected through a carbon atom and each may be unsubstituted or substituted by one or two C.sub.1-2 alkyl groups;
• R.sub.14 is hydrogen or R.sub.7 ;
• or when R.sub.8 and R.sub.14 are as NR.sub.8 R.sub.14 they may together with the nitrogen form a 5 to 7 membered ring optionally containing one or more additional heteroatoms selected from O, N, or S;
• R.sub.15 is C(O)R.sub.14, C(O)NR.sub.4 R.sub.14, S(O).sub.2 R.sub.7, or S(O).sub.2 NR.sub.4 R.sub.14 ;
• provided that:
• a) when Z is O, X.sub.2 is oxygen, and X is YR.sub.2, then R.sub.3 is other than hydrogen;
• b) when R.sub.12 is N-pyrazolyl, N-imidazolyl, N-triazolyl, N-pyrrolyl, N-piperazinyl, N-piperidinyl, or N-morpholinyl, then q is not 1;
• or the pharmaceutically acceptable salts thereof.